-logo-1200x675.PNG?v=20210211152252){kind=logo}
Profound Medical Corp. (TSE:PRN – Free Report) – Research analysts at Raymond James issued their Q1 2026 earnings per share estimates for shares of Profound Medical in a research note issued on Tuesday, February 18th. Raymond James analyst M. Freeman expects that the company will post earnings per share of ($0.34) for the quarter. Raymond James currently has a “Strong-Buy” rating on the stock. The consensus estimate for Profound Medical’s current full-year earnings is ($1.90) per share. Raymond James also issued estimates for Profound Medical’s Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.27) EPS and Q4 2026 earnings at ($0.20) EPS.
Profound Medical Trading Up 4.2 %
Shares of PRN opened at C$10.51 on Wednesday. The stock has a fifty day moving average price of C$10.03 and a two-hundred day moving average price of C$10.86. The company has a debt-to-equity ratio of 20.05, a quick ratio of 14.98 and a current ratio of 6.12. Profound Medical has a 52-week low of C$7.90 and a 52-week high of C$15.75. The company has a market cap of C$221.47 million, a price-to-earnings ratio of -5.45 and a beta of 0.81.
Insider Buying and Selling
In other news, Senior Officer Thomas Michael Tamberrino acquired 13,333 shares of Profound Medical stock in a transaction dated Tuesday, December 10th. The stock was bought at an average cost of C$10.65 per share, with a total value of C$141,996.45. Also, Director Arun Menawat Dr. acquired 20,000 shares of Profound Medical stock in a transaction dated Tuesday, December 10th. The shares were purchased at an average cost of C$10.65 per share, with a total value of C$213,000.00. 8.62% of the stock is owned by insiders.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
Further Reading
Receive News & Ratings for Profound Medical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Profound Medical and related companies with MarketBeat.com’s FREE daily email newsletter.
